Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for ew
135.85
+2.83 (2.13%)
Mar 2 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 132.61 - 136.06
52 week 68.16 - 137.58
Open 132.62
Vol / Avg. 0.00/998,882.00
Mkt cap 14.35B
P/E 18.07
Div/yield     -
EPS 7.52
Shares 107.84M
Beta 0.64
Inst. own 86%
May 14, 2015
Edwards Lifesciences Corp Annual Shareholders Meeting - 1:00PM EDT - Add to calendar
May 8, 2015
Edwards Lifesciences Corp Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Apr 22, 2015
Q1 2015 Edwards Lifesciences Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 18, 2015
Edwards Lifesciences Corp at BTIG Snowbird Conference
Feb 11, 2015
Edwards Lifesciences Corp at Leerink Global Healthcare Conference
Feb 3, 2015
Q4 2014 Edwards Lifesciences Corp Earnings Call - Webcast
Feb 3, 2015
Q4 2014 Edwards Lifesciences Corp Earnings Release
Dec 8, 2014
Edwards Lifesciences Corp Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 17.67% 34.92%
Operating margin 21.50% 49.25%
EBITD margin - 23.96%
Return on average assets 12.74% 26.02%
Return on average equity 20.69% 43.42%
Employees 9,100 -
CDP Score - -

Address

1 Edwards Way
IRVINE, CA 92614-5688
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 52
Bio & Compensation  - Reuters
Patrick B. Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 57
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Valve Replacement
Age: 48
Bio & Compensation  - Reuters
Kieran T. Gallahue Director
Age: 51
Bio & Compensation  - Reuters
Nicholas J. Valeriani Director
Age: 56
Bio & Compensation  - Reuters
Michael R. Bowlin Independent Director
Age: 71
Bio & Compensation  - Reuters
John T. Cardis Independent Director
Age: 72
Bio & Compensation  - Reuters